Cohance Lifesciences Ltd share price logo

Cohance Lifesciences Ltd Share Price(COHANCE)

Small Cap

Healthcare Sector

Check the latest share price of Cohance Lifesciences Ltd, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.

₹1075.2▲1.87%

as on 04:01PM, 21 May 2025

NSE

bell
The current prices are delayed by 15 mins, login to check live prices.

Cohance Lifesciences Ltd Performance

Get real-time share price information, day’s high and low, historical returns and market stats.

  • Day's Low

    Day's High

    ₹1,043.7
    Day's Price Range
    ₹1,082.8

  • 52 Week's Low

    52 Week's High

    ₹598
    52-Week Price Range
    ₹1,360
1 Month Return-12.2 %
3 Month Return-13.94 %
1 Year Return+ 67.41 %
3 Year Return+ 103.69 %
5 Year Return+ 552.23 %
Previous Close₹1,055.50
Open₹1,055.50
Volume2.22L
Upper Circuit₹1,266.60
Lower Circuit₹844.40

Cohance Lifesciences Ltd Fundamentals & Key Indicators

Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.

Market Cap

₹26,869.33 Cr

Return on Equity (ROE)

14.31

PE Ratio (TTM)

96.13

Return on capital employed (ROCE)

18.82

Industry PE ratio

55.72

Beta (LTM)

0.53

P/B Ratio

8.38

Dividend Yield

0

PEG Ratio

-26.7

Quarterly Earnings Growth YOY

78.16

EPS (TTM)

11.8

Sector

Pharmaceuticals

Book Value

80.56

Technical Analysis

Bearish

View Technical Analysis

How to invest in Cohance Lifesciences Ltd?

Investing in Cohance Lifesciences Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Cohance Lifesciences Ltd or COHANCE on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

For example: You can buy 10 shares of Cohance Lifesciences Ltd or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Cohance Lifesciences Ltd with just a few clicks!

Cohance Lifesciences Ltd Stock's Interest Amongst Investors

18%

Period May 21, 2025 to Apr 21, 2025. Change in 30 Days vs previous period

Search interest for Cohance Lifesciences Ltd Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Cohance Lifesciences Ltd Valuation

Track how the P/E of Cohance Lifesciences Ltd has moved over time to understand valuation trends.

Cohance Lifesciences Ltd in the last 5 years

  • Overview

  • Trends

Lowest (4.48x)

March 30, 2020

Industry (55.72x)

May 20, 2025

Today (96.13x)

May 20, 2025

Highest (139.56x)

November 5, 2024

LowHigh

Today’s Price to Earnings Ratio: 96.13x

Analysts Recommendation on Cohance Lifesciences Ltd

Get updated buy, sell, and hold recommendations by analysts on Cohance Lifesciences Ltd.

based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

100% of analysts recommend a 'BUY' rating for Cohance Lifesciences Ltd. Average target price of ₹1396.67

Source: S&P Global Market Intelligence

Analysts Forecast on Cohance Lifesciences Ltd

Get share price movements and forecasts by analysts on Cohance Lifesciences Ltd.

Cohance Lifesciences Ltd price forecast by 6 analysts

Upside of32.32%

High

₹1500

Target

₹1396.67

Low

₹1290

Cohance Lifesciences Ltd target price ₹1396.67, a slight upside of 32.32% compared to current price of ₹1075.2. According to 6 analysts rating.

Source: S&P Global Market Intelligence

Cohance Lifesciences Ltd Financials

Get the annual and quarterly financial summary of Cohance Lifesciences Ltd, including revenue, profit, loss and more.

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue

(in ₹ Cr)

220 (0%)253 (15%)231 (9%)258 (12%)307 (19%)
Net Income

(in ₹ Cr)

47 (0%)53 (14%)61 (14%)82 (35%)83 (2%)
Net Profit Margin21.27% (0%)21.10% (1%)26.34% (25%)31.81% (21%)27.12% (15%)
Value in ₹ crore
Details2021202220232024
Total Assets

(in ₹ Cr)

1361 (0%)1806 (33%)1960 (8%)2244 (15%)
Total Liabilities

(in ₹ Cr)

296 (0%)286 (4%)210 (26%)188 (10%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow

(in ₹ Cr)

359 (0%)329 (8%)270 (18%)493 (83%)371 (25%)

Cohance Lifesciences Ltd Index Inclusions

Nifty MNC

₹28,157.20

1.1 (▲306%)

S&P BSE 250 SmallCap

₹6,610.56

0.45 (▲29.71%)

S&P BSE 400 MidSmallCap

₹11,681.20

0.7 (▲81.77%)

BSE 500

₹35,742.34

0.64 (▲228.77%)

Nifty Smallcap 250

₹16,437.10

0.42 (▲68.45%)

Nifty MidSmallcap 400

₹19,250.80

0.66 (▲126.2%)

Nifty 500

₹22,730.65

0.64 (▲145.05%)

S&P BSE SmallCap Select

₹7,556.71

0.47 (▲34.98%)

BSE Healthcare

₹42,593.73

0.93 (▲390.48%)

BSE Small-Cap

₹51,200.19

0.51 (▲262.16%)

Cohance Lifesciences Ltd Earnings and Dividends

View detailed summary of the earnings and dividend history of Cohance Lifesciences Ltd.

  • Cohance Lifesciences Ltd Earnings Results

    Cohance Lifesciences Ltd’s net profit jumped 77.28% since last year same period to ₹82.88Cr in the Q3 2024-2025. On a quarterly growth basis, Cohance Lifesciences Ltd has generated 0.81% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Cohance Lifesciences Ltd Dividends September,2022

    In the quarter ending June 2022, Cohance Lifesciences Ltd has declared dividend of ₹1 - translating a dividend yield of 1.04%.

    Read More about Dividends

Cohance Lifesciences Ltd Shareholding Pattern

View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Cohance Lifesciences Ltd.

InvestorsHoldings %Quarterly Trend3M change
Promoter Holdings
50.1%
0.00
Foreign Institutions
11.05%
0.00
Mutual Funds
13.04%
0.00
Retail Investors
22.23%
0.00
Others
3.58%
0.00

Cohance Lifesciences Ltd vs Peers

Compare market cap, revenue, PE, and other key metrics of Cohance Lifesciences Ltd with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd
BUY26,869.33110.45%0.523001,051
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY15,759.5528.4%0.57726,702
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA5,192.674.62%0.79-38875
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY13,680.0339.84%0.682181,296
Poly Medicure Ltd
Poly Medicure Ltd
HOLD24,825.81167.68%0.552581,375
See all

Cohance Lifesciences Ltd News & Key Events

Latest news and events at one place to help you take investing decisions in Cohance Lifesciences Ltd.

  • Suven Pharmaceuticals Rebrands to Cohance Lifesciences - 08 May, 2025

    Suven Pharmaceuticals has changed its name to Cohance Lifesciences, effective May 7, 2025. This rebranding reflects the company's commitment to innovation in the CDMO sector.

  • Suven Pharmaceuticals Targets $1 Billion Revenue by 2030 - 05 May, 2025

    Suven Pharmaceuticals reports increased engagement at industry events, focusing on advanced capabilities like ADCs and peptides. The company aims for $1 billion in revenue by 2030, driven by CDMO momentum.

  • Suven Pharmaceuticals Merger with Cohance Approved - 25 Apr, 2025

    The merger between Suven Pharmaceuticals and Cohance Lifesciences will take effect on May 1, 2025, aiming to create a diversified CDMO platform. The National Company Law Tribunal approved the merger on March 27, with plans for aggressive expansion and a revenue target of Rs 6000 crore by FY29.

  • Suven Pharma Advances with Merger and Global Engagement - 23 Apr, 2025

    Suven Pharmaceuticals received regulatory approval for increasing foreign investment post-merger with Cohance Lifesciences. The company also sees heightened interest from global pharma firms seeking alternatives to China.

Insights on Cohance Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, COHANCE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, 46.75 Cr → 82.88 Cr (in ₹), with an average increase of 12.9% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 10.84% to 11.05% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 248.85 Cr → 322.86 Cr (in ₹), with an average increase of 12.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 147.8% return, outperforming this stock by 44.1%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 50.10% of holdings in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 13.15% to 13.04% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 22.37% to 22.23% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, COHANCE stock has moved down by -12.2%

About Cohance Lifesciences Ltd

Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company engaged in the development and manufacturing of New Chemical Entity (NCE) based Intermediates and Active Pharmaceutical Ingredients, Speciality Chemicals, and formulated drugs. In 2019, Suven Life Sciences Ltd. transferred the CRAMS business to the Company, and the equity shares of the Company were listed for trading in March 2020. The Board approved and recommended the issue of 1:1 bonus shares in August 2020, and the number of shares increased from 127,282,478 to 254,564,956. In 2021, Suven invested 120 crore in investing and has a capex plan of Rs.320crore. In 2022, the Company also filed 17 ANDAs for which 9 were approved and 8 products were launched. The Company acquired 100 stake in Casper Pharma Private Limited in 2022, making it a Wholly Owned Subsidiary. In this way, Suven Pharmaceuticals Limited is endeavouring to be the leading biopharmaceutical company in global markets.

Revenue: ₹307.15Cr as on December 2024 (Q4 24)
Net Profit: ₹83.29Cr as on December 2024 (Q4 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
OrganisationCohance Lifesciences Ltd
IndustryPharmaceuticals
CEOAnnaswamy Vaidheesh
E-voting on sharesClick here to vote

Indian Mutual Funds that own Cohance Lifesciences Ltd

Check out the Mutual Funds with significant holdings in Cohance Lifesciences Ltd.

FAQs

What is Cohance Lifesciences Ltd price today?

Cohance Lifesciences Ltd share price today stands at ₹1075.2, Open: ₹1055.5, Previous Close: ₹1055.5, High: ₹1082.8, Low: ₹1043.7, 52 Week High: ₹1360, 52 Week Low: ₹598.

How to Buy Cohance Lifesciences Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Cohance Lifesciences Ltd shares

What are today's traded volumes of Cohance Lifesciences Ltd?

Today's traded volume of Cohance Lifesciences Ltd(COHANCE) is 2.22L.

What is today's market capitalisation of Cohance Lifesciences Ltd?

Today's market capitalisation of Cohance Lifesciences Ltd(COHANCE) is ₹26,869.33 Cr.

What is the 52 Week High and Low Range of Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd (COHANCE)
Price
52 Week High
₹1360
52 Week Low
₹598

How much percentage Cohance Lifesciences Ltd is down from its 52 Week High?

Cohance Lifesciences Ltd (COHANCE) share price is ₹1075.2. It is down -20.94% from its 52 Week High price of ₹1360

How much percentage Cohance Lifesciences Ltd is up from its 52 Week low?

Cohance Lifesciences Ltd (COHANCE) share price is ₹1075.2. It is up 79.80% from its 52 Week Low price of ₹598